Deucravacitinib

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 294 publications

Successful Treatment of Pityriasis Rubra Pilaris With Deucravacitinib.

Successful Treatment of Pityriasis Rubra Pilaris With Deucravacitinib.

Journal: JAMA dermatology

Published: January 21, 2026

Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: Results from an early-terminated open-label trial.

Deucravacitinib for the treatment of moderate-to-severe palmoplantar pustulosis: Results from an early-terminated open-label trial.

Journal: JAAD international

Published: January 19, 2026

Successful treatment of cutaneous sarcoidosis with deucravacitinib, a selective TYK2 inhibitor.

Successful treatment of cutaneous sarcoidosis with deucravacitinib, a selective TYK2 inhibitor.

Journal: JAAD case reports

Published: December 25, 2025

Off-Label Use of Deucravacitinib in Dermatology: A Systematic Review.

Off-Label Use of Deucravacitinib in Dermatology: A Systematic Review.

Journal: Journal of cutaneous medicine and surgery

Published: December 13, 2025

Deucravacitinib could be an effective and safe choice in patients affected with psoriasis and atopic dermatitis (Psorema)?

Deucravacitinib could be an effective and safe choice in patients affected with psoriasis and atopic dermatitis (Psorema)?

Journal: Italian journal of dermatology and venereology

Published: December 11, 2025

Rapid and Successful Treatment of Generalized Granuloma Annulare With Deucravacitinib.

Rapid and Successful Treatment of Generalized Granuloma Annulare With Deucravacitinib.

Journal: Cureus

Published: December 08, 2025

Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review.

Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review.

Journal: Annals of medicine

Published: December 02, 2025

Novel use of deucravacitinib for treatment of recalcitrant TIF1-gamma dermatomyositis.

Novel use of deucravacitinib for treatment of recalcitrant TIF1-gamma dermatomyositis.

Journal: JAAD case reports

Published: November 28, 2025

Two-Year Real-World Effectiveness of Deucravacitinib 6 mg in Psoriasis: A Single-Center Analysis Stratified by Body Mass Index or Age in a Japanese Cohort.

Two-Year Real-World Effectiveness of Deucravacitinib 6 mg in Psoriasis: A Single-Center Analysis Stratified by Body Mass Index or Age in a Japanese Cohort.

Journal: The Journal of dermatology

Published: November 14, 2025

The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta-Analysis Study.

The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta-Analysis Study.

Journal: Journal of cosmetic dermatology

Published: November 13, 2025

Deucravacitinib in Psoriasis: Evidence, Gaps, and Place in Therapy.

Deucravacitinib in Psoriasis: Evidence, Gaps, and Place in Therapy.

Journal: International journal of dermatology

Published: November 06, 2025

Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study.

Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study.

Journal: Journal of cosmetic dermatology

Published: November 05, 2025

Showing 1-12 of 294

Last Updated: 02/24/2026